Natural supplements in breast cancer therapy: translational evidence, clinical safety, and emerging challenges - Summary - MDSpire

Natural supplements in breast cancer therapy: translational evidence, clinical safety, and emerging challenges

  • By

  • Sirajunisa Talath

  • Mohamed El-Tanani

  • Adil Farooq Wali

  • Syed Arman Rabbani

  • Bhoomendra Bhongande

  • Walaa Ibraheem

  • Ashot Avagimyan

  • Karolina Hoffmann

  • Ioannis Ilias

  • Sorina Ispas

  • Maggio Viviana

  • Anna Paczkowska

  • Manfredi Rizzo

  • April 30, 2026

  • 0 min

Share

Objective:

To focus on the clinical safety features and translational utility of natural supplements against breast cancer, emphasizing both safety and efficacy.

Key Findings:
  • Natural supplements may have anticancer, antioxidant, and anti-inflammatory effects, but robust clinical evidence for efficacy is limited, necessitating further randomized trials.
  • Standardization and safety concerns are significant barriers to clinical use, highlighting the need for more robust evidence.
Interpretation:

While natural supplements show promise in breast cancer management, their integration into treatment requires careful consideration of safety, efficacy, and adherence to regulatory standards.

Limitations:
  • Lack of large-scale randomized controlled trials.
  • Inadequate bioavailability of many natural supplements.
  • Potential herb-drug interactions that could complicate treatment.
  • Need for interdisciplinary collaboration to address these limitations.
Conclusion:

Natural supplements have potential in breast cancer treatment but require evidence-based practices and further research to ensure safety and efficacy.

Original Source(s)

Natural supplements in breast cancer therapy: translational evidence, clinical safety, and emerging challenges

  • by Sirajunisa Talath, Mohamed El-Tanani, Adil Farooq Wali, Syed Arman Rabbani, Bhoomendra Bhongande, Walaa Ibraheem, Ashot Avagimyan, Karolina Hoffmann, Ioannis Ilias, Sorina Ispas, Maggio Viviana, Anna Paczkowska, Manfredi Rizzo

  • April 30, 2026

Related Content

Data requirements of an informative, directive, and preventive mobile health application for gastric cancer

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy

PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report